STOCK TITAN
  1. Home
  2. News
  3. MOLN

Molecular Partners AG American Depositary Shares - MOLN STOCK NEWS

Welcome to our dedicated page for Molecular Partners American Depositary Shares news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on Molecular Partners American Depositary Shares stock.

Molecular Partners AG (NASDAQ: MOLN) is a clinical-stage biopharmaceutical company headquartered in Zurich-Schlieren, Switzerland, with an additional office in Concord, Massachusetts. The company specializes in the development of DARPin therapeutics, a new class of custom-built protein drugs designed to tackle complex diseases such as cancer and sight-threatening disorders.

Molecular Partners has a diversified product pipeline focusing primarily on oncology and ophthalmology. In the field of oncology, the firm is advancing multiple DARPin candidates including MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia, which is currently in Phase 1/2a clinical trials. The company's latest innovation, the Switch-DARPin platform, aims to deliver multispecific candidates for conditional activation of targeted immune responses. Another exciting area of development is the Radio-DARPin Therapy (RDT) platform, which uses DARPin technology to enhance tumor uptake and reduce kidney reabsorption of radiopharmaceutical drugs, with lead candidate MP0712 targeting DLL3 in small-cell lung cancer.

On the ophthalmology front, Molecular Partners is developing therapies for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. The firm's dedication to innovation is further evidenced by its strategic collaborations with prominent pharmaceutical companies such as Novartis and Orano Med.

Financially, the company reported CHF 186.9 million in cash and short-term deposits as of year-end 2023 and maintains a strong cash runway well into 2026. Despite a net loss of CHF 62 million for 2023, Molecular Partners continues to invest in its robust pipeline and transformative research initiatives.

Recent news highlights Molecular Partners' presentation at the 42nd Annual J.P. Morgan Healthcare Conference where they provided a business overview and 2024 outlook. The company anticipates significant milestones in 2024, including further clinical data from its lead oncology program MP0533 and progression of its RDT and Switch-DARPin platforms.

For more information, visit www.molecularpartners.com, or follow them on LinkedIn and X @MolecularPrtnrs.

News

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Molecular Partners AG (MOLN) announces progress on T-cell engager MP0533 for patients with r/r AML and AML/MDS, Radio-DARPin Therapy (RDT) platform, and introduction of first program from the Switch-DARPin platform. The company also provides its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference, including clinical trial updates and future milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.79%
Tags
none
-
News

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Rhea-AI Summary
Molecular Partners AG (MOLN) and Orano Med collaborate to develop Radio-DARPin therapeutics using 212Pb radioisotope as a payload for cancer treatment. The collaboration covers multiple oncology targets, including DLL3, with anticipated first-in-human studies in 2025. Both companies will share costs for preclinical and clinical development, leveraging their unique capabilities to enable rapid clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.79%
Tags
none
-
News

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Rhea-AI Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) to present at the 42nd Annual J.P. Morgan Healthcare Conference and upcoming investor events in Switzerland. The conference will feature presentations by the CEO and COO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.42%
Tags
conferences
News

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Rhea-AI Summary
Molecular Partners AG (MOLN) presents positive initial clinical data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Initial antitumor activity and acceptable safety profile observed in early dose-escalation cohorts. A previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range three. MP0533 monotherapy continues to demonstrate an acceptable safety profile across the first four dosing cohorts, with no dose-limiting toxicities observed. Phase 1/2a trial remains ongoing with patients being enrolled in the fifth of seven planned dose-escalation cohorts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Rhea-AI Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) will present at the 15th Annual Protein & Antibody Engineering European Summit (PEGS Europe) to showcase the versatility of DARPin designs in conditional activation of the immune system to fight tumors. The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions, aiming to minimize damage to healthy cells. The review will include differentiated mechanisms of action such as tumor-localized activation, avidity-driven selectivity, and the novel SWITCH-DARPin approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Rhea-AI Summary
Molecular Partners AG will present additional positive data from its Phase 1 study of MP0317 in patients with advanced solid tumors. The study shows tumor-localized CD40 activation and a favorable safety profile. Patient recruitment for the dose-escalation portion is complete, with final results expected in H1 2024. The data support further clinical evaluation of MP0317, including combination studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.53%
Tags
clinical trial
News

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

Rhea-AI Summary
Molecular Partners AG will present preliminary data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data indicate an acceptable safety profile with no dose-limiting toxicity or Grade ≥3 adverse reactions. One patient in the third treatment cohort achieved a response. The study is enrolling its fifth cohort, and additional data will be presented at the ASH Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.52%
Tags
conferences clinical trial
-
News

Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

Rhea-AI Summary
Molecular Partners AG, a clinical-stage biotech company, will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on November 3, 2023. The event will feature Patrick Amstutz, CEO, and Dr. Philippe Legenne, acting CMO. A live webcast will be available on the company's website, with a replay archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
conferences
-
News

Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio

Rhea-AI Summary
Molecular Partners announces corporate highlights and unaudited financial results for Q3 2023. Phase 1 dose escalation recruitment completed for MP0317 in advanced solid tumors. MP0533 Phase 1/2a recruitment in r/r AML patients proceeding as planned. Radio-DARPin Therapy platform continues to progress. Company funded well into 2026 with CHF 207 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
earnings
News

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Rhea-AI Summary
Molecular Partners announces new data from its Radio-DARPin Therapy (RDT) platform, showing increased tumor uptake and reduced accumulation in kidneys. The engineering solutions applied to optimize the RDT platform are transferrable to different tumor-associated antigens, potentially expanding the target space for radioligand therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none

FAQ

What is the current stock price of Molecular Partners American Depositary Shares (MOLN)?

The current stock price of Molecular Partners American Depositary Shares (MOLN) is $5.2851 as of November 22, 2024.

What is the market cap of Molecular Partners American Depositary Shares (MOLN)?

The market cap of Molecular Partners American Depositary Shares (MOLN) is approximately 199.7M.

What is Molecular Partners AG?

Molecular Partners AG is a clinical-stage biopharmaceutical company specializing in the development of DARPin therapeutics to address complex diseases such as cancer and retinal disorders.

What are DARPin therapeutics?

DARPin therapeutics are a new class of custom-built protein drugs with high affinity and specificity, designed to tackle complex medical challenges that other drug modalities cannot readily address.

What is the focus of Molecular Partners' product pipeline?

Molecular Partners' product pipeline focuses mainly on oncology and ophthalmology, with multiple DARPin candidates in various stages of preclinical and clinical development.

What is the Switch-DARPin platform?

The Switch-DARPin platform is a novel technology that provides a logic-gated 'on/off' function to multispecific DARPin candidates, enabling conditional activation of targeted immune responses.

What is the Radio-DARPin Therapy (RDT) platform?

The RDT platform leverages DARPin technology to enhance tumor uptake and reduce kidney reabsorption of radiopharmaceutical drugs, aiming to improve the efficacy and safety of radiotherapy treatments.

Who are some of Molecular Partners' strategic partners?

Molecular Partners has formed strategic collaborations with leading pharmaceutical companies such as Novartis and Orano Med to advance its DARPin therapeutics.

What are some key financial highlights for Molecular Partners?

As of year-end 2023, Molecular Partners reported CHF 186.9 million in cash and short-term deposits, with a cash runway projected well into 2026. The company incurred a net loss of CHF 62 million for the year.

What recent milestones has Molecular Partners achieved?

Recent milestones include presenting a business overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference and advancing several clinical and preclinical programs in oncology and ophthalmology.

What is Molecular Partners' lead oncology program?

The lead oncology program is MP0533, a novel tetra-specific T cell-engaging DARPin currently in Phase 1/2a clinical trials for the treatment of acute myeloid leukemia.

Where can I find more information about Molecular Partners?

For more information, visit Molecular Partners' website at www.molecularpartners.com, or follow them on LinkedIn and X @MolecularPrtnrs.

Stock MOLN logo
Molecular Partners AG American Depositary Shares

Nasdaq:MOLN

MOLN Rankings

#3868 Ranked by Market Cap
N/A Ranked by Dividends

MOLN Stock Data

199.66M
40.33M
5.31%
0.15%
Biotechnology
Healthcare
Link
United States of America
Schlieren